Alisertib

Target: Alisertib targets Aurora A kinase, also known as AURKA, with selective inhibitory activity.

Mechanism of Action: Alisertib can provide an Aurora A kinase-binding module for PROTAC development. After derivatization at a tolerated position, the alisertib-based ligand can be joined through a linker to an E3 ligase ligand. The kinase-binding end recognizes Aurora A, while the E3-binding end recruits ubiquitin-ligase machinery. Degradation depends on forming a ternary complex that positions Aurora A for ubiquitin transfer. If productive ubiquitination occurs, polyubiquitinated Aurora A is directed to the proteasome, enabling target removal rather than catalytic inhibition alone. This establishes a testable protein-depletion mechanism for research assays.

• Kinase Degrader Development: Alisertib can serve as a warhead ligand in PROTAC designs aimed at degrading Aurora A kinase. By conjugating it to an E3 ligase recruiter, researchers can test whether ternary complex formation enhances ubiquitination and promotes proteasome-dependent removal, enabling functional interrogation of Aurora A biology beyond inhibition alone.

• Aurora A Function Probing: Use Alisertib-based PROTACs to dissect Aurora A–driven mitotic phenotypes, including spindle assembly and chromosome segregation. Targeted degradation can reveal degradation-specific effects, such as duration-dependent loss of signaling, and help distinguish scaffolding versus catalytic contributions by comparing degradation potency with kinase inhibition readouts.

• E3 Ligase Recruiter Optimization: Alisertib can be paired with diverse E3 ligase-binding modules to optimize degradation efficiency and selectivity. Systematic variation of linker length, attachment site, and recruiter identity supports mapping of productive ternary complexes, improving ubiquitination kinetics and stabilizing active conformations that drive robust proteasomal turnover.

• Proteasome-Dependent Mechanism Studies: Alisertib-containing PROTACs are suitable for mechanistic experiments that confirm degradation is mediated by the ubiquitin–proteasome pathway. Researchers can employ proteasome or neddylation pathway perturbations and monitor target loss, ubiquitin conjugates, and ternary complex stability to validate causal links between recruitment, ubiquitination, and degradation.

• Comparative Degrader vs Inhibitor: Alisertib PROTACs enable direct comparisons between catalytic inhibition and degradation-driven biology. By benchmarking cellular outcomes such as cell-cycle arrest, apoptosis markers, and mitotic progression against matched inhibitor controls, studies can quantify whether complete protein depletion produces stronger or qualitatively distinct phenotypes relative to transient kinase blockade.

Alisertib is an Aurora A kinase inhibitor with a fused pyrimido-benzazepine scaffold that can inform mitotic-kinase degrader design. Its carboxylic acid and arylamino heterocycle provide a defined warhead architecture for linker feasibility studies. This molecule is described in detail below.

Structure: The structure features a chloro fluoro-methoxy aryl substituted pyrimido-benzazepine core connected through an anilino linkage to a methoxybenzoic acid. The carboxylic acid, aryl ether, and fused heteroaromatic system provide strong polarity and conformational rigidity.

Reactivity: The benzoic acid offers an obvious chemical handle for amide-linked linker attachment, but this position must be confirmed as solvent-tolerant because acidic groups may contribute to binding, solubility, or cellular behavior. PEG, alkyl, or amide-rich linkers may be coupled to CRBN or VHL ligands; linker length should be screened carefully because Aurora A degradation requires not only kinase binding but also productive E3 proximity.